Senti Biosciences’ (SNTI) Buy Rating Reiterated at Chardan Capital

Chardan Capital restated their buy rating on shares of Senti Biosciences (NASDAQ:SNTI) in a research report released on Friday,Benzinga reports. They currently have a $12.00 price objective on the stock.

Senti Biosciences Trading Up 2.2 %

SNTI opened at $3.32 on Friday. Senti Biosciences has a 1-year low of $1.52 and a 1-year high of $16.94. The business has a 50 day moving average of $3.48 and a 200-day moving average of $3.66. The stock has a market capitalization of $86.33 million, a price-to-earnings ratio of -0.21 and a beta of 2.32.

Senti Biosciences (NASDAQ:SNTI) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.67) EPS for the quarter, beating analysts’ consensus estimates of ($3.13) by $2.46. The company had revenue of $5.86 million for the quarter, compared to analyst estimates of $2.80 million. Equities analysts predict that Senti Biosciences will post -14.54 EPS for the current year.

Hedge Funds Weigh In On Senti Biosciences

A hedge fund recently bought a new stake in Senti Biosciences stock. Virtu Financial LLC acquired a new stake in shares of Senti Biosciences, Inc. (NASDAQ:SNTI) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 13,356 shares of the company’s stock, valued at approximately $47,000. Virtu Financial LLC owned approximately 0.28% of Senti Biosciences at the end of the most recent quarter. 25.73% of the stock is currently owned by institutional investors.

About Senti Biosciences

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.